<DOC>
	<DOCNO>NCT02032303</DOCNO>
	<brief_summary>Study design Investigators aim perform prospective , single-center , investigator-initiated , randomize study compare Adenosine-induced coronary vasodilatation load dose Ticagrelor either Prasugrel Percutaneous Coronary Intervention . Patients acute coronary syndrome undergo Percutaneous Coronary Intervention enrol study randomize , 1:1 ratio , receive load dose Ticagrelor ( 180 mg ) Prasugrel ( 60 mg ) . In patient non-ST elevation myocardial infarction drug administer coronary anatomy know , avoid bleeding due prasugrel , patient suitable coronary artery bypass graft recommended European Society Cardiology guideline ( Class IB ) ( 10 ) . In patient ST elevation myocardial infarction , instead , prasugrel ticagrelor administrate procedure , accord European Society Cardiology guideline ( Class IB ) ( 11 ) . Coronary Flow Reserve record intracoronary Doppler Flow Wire stent implantation procedure baseline 2-minute later adenosine intravenous administration incremental dose 50 , 80 , 110 140 ug/Kg/min 2 minute interval infusion . Coronary Flow Reserve ability myocardium increase blood flow response maximal exercise . Doppler Flow Wire allow measure increase express ratio maximal vasodilation flow rest . Coronary Flow Reserve routinely measure patient acute coronary syndrome , without increase risk adverse event patient neither adjunctive cost National Health System . Furthermore , Plasma concentration Ticagrelor main metabolite ( AR-C124910XX ) measure venous blood collect end procedure . . In patient require second Percutaneous Coronary Intervention , example multivessel disease , measure repeat manner .</brief_summary>
	<brief_title>Assessment Coronary Flow Reserve Doppler Flow WIre Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention : Differences Between Loading Dose Prasugrel Ticagrelor .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>• Patients acute coronary syndrome undergo Percutaneous Coronary Intervention stent implantation ; Patients ≥ 18 ≤ 75 year old . Signed informed consent ; • Patients stable angina ; prior myocardial infarction ; prior revascularization ( Percutaneous Coronary Intervention coronary artery bypass graft ) ; Ticagrelor contraindication ( history intracranial hemorrhage , active pathological bleeding , severe hepatic impairment ) ; Prasugrel contraindication ( patient weigh less 60 kg , patient previous stroke transient ischemic attack , patient age 75 year old ) ; major periprocedural complication ; suboptimal Percutaneous Coronary Intervention result ( residual stenosis &gt; 20 % ) ; glomerular filtration rate &lt; 30 ml/min require haemodialysis ; Nonsinus rhythm ; severe chronic obstructive pulmonary disease ; requirement oral anticoagulant ; risk bleed bradycardic event ; ejection fraction &lt; 45 % ; Cardiogenic shock ; Severe leave ventricular hypertrophy ; severe valvular disease ; diffuse coronary atherosclerosis ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>